These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16519036)

  • 21. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes.
    Hermansen K; Vaaler S; Madsbad S; Dalgaard M; Zander M; Begtrup K; Soendergaard K
    Metabolism; 2002 Jul; 51(7):896-900. PubMed ID: 12077738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections.
    Li FF; Fu LY; Zhang WL; Su XF; Wu JD; Sun J; Ye L; Ma JH
    J Diabetes Res; 2016; 2016():1028945. PubMed ID: 26839889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The IMPROVE study--a multinational, observational study in type 2 diabetes: data from the Polish cohort.
    Gumprecht J; Zurawska G; Wolnik B; Dzida G
    Endokrynol Pol; 2008; 59(6):460-6. PubMed ID: 19347809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
    Valentine WJ; Pollock RF; Plun-Favreau J; White J
    Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK; Schmüser C; Askonen K; Saukkonen T
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
    Almansari A; Khader S; Kharawagh A; AbdelFattah W; Badawy T
    Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.
    Rave K; Heinemann L; Puhl L; Gudat U; Woodworth JR; Weyer C; Heise T
    Diabetes Care; 1999 May; 22(5):865-6. PubMed ID: 10332707
    [No Abstract]   [Full Text] [Related]  

  • 29. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling of Pharmacokinetic Profiles of Insulin Aspart and Biphasic Insulin Aspart 30/70.
    Kulesh VS; Drai RV; Zinnatulina BR; Makarenko IE; Pilyus FG; Khokhlov AL
    J Clin Pharmacol; 2022 Sep; 62(9):1086-1093. PubMed ID: 35320591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study--the Iran subgroup of the IMPROVE™ study.
    Esteghamati A; Rajabian R; Amini M; Bahrami A; Khamseh ME; Afkhami-Ardekani M; Rizi EP
    Endokrynol Pol; 2010; 61(4):364-70. PubMed ID: 20806180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
    Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter, open-label, non-randomized, non-interventional observational study of safety of treatment initiation with a biphasic insulin aspart.
    Wolnik B; Hak L
    Expert Opin Drug Saf; 2013 Mar; 12(2):137-44. PubMed ID: 23289795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.
    Luzio S; Dunseath G; Peter R; Pauvaday V; Owens DR
    Diabetologia; 2006 Jun; 49(6):1163-8. PubMed ID: 16596358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biphasic insulin aspart in the treatment of type 2 diabetes mellitus.
    Cucinotta D; Russo GT
    Expert Opin Pharmacother; 2009 Dec; 10(17):2905-11. PubMed ID: 19929709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.
    Balaji V; Balaji MS; Alexander C; Srinivasan A; Suganthi SR; Thiyagarajah A; Seshiah V
    Gynecol Endocrinol; 2012 Jul; 28(7):529-32. PubMed ID: 22468861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Supplemental insulin therapy of type 2 diabetes follows the example of nature. Replace what the patient lacks].
    MMW Fortschr Med; 2004 May; 146(22):47. PubMed ID: 15373112
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmaceutical development and clinical experiment of new antidiabetic drugs, premixed preparations of insulin lispro (Humalog Mix 25 and Humalog Mix 50) and intermediate-acting insulin lispro (Humalog N)].
    Awa T; Nakata T; Shigeta H
    Nihon Yakurigaku Zasshi; 2005 Aug; 126(2):143-51. PubMed ID: 16205018
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of biphasic insulin aspart 30 combined with metformin on glycaemic control in obese people with type 2 diabetes.
    Ascić-Buturović B
    Bosn J Basic Med Sci; 2007 Nov; 7(4):335-8. PubMed ID: 18039192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.